Current
9.3×
5-Year Average
9.3×
All-Time High
83.7×
All-Time Low
4.8×
P/S Ratio daily chart for Vertex Pharmaceuticals (VRTX)
Jun 8, 2021 – Jun 5, 2026 · 1,255 trading days
Historical P/S Ratio for Vertex Pharmaceuticals (VRTX) from 2001 to 2025
| 2025 | $115.11B | $12.04B | 9.6× | +0.1× | |
| 2024 | $103.70B | $11.02B | 9.4× | -1.2× | |
| 2023 | $104.86B | $9.87B | 10.6× | +2.3× | |
| 2022 | $74.19B | $8.93B | 8.3× | +0.9× | |
| 2021 | $55.91B | $7.57B | 7.4× | -2.5× | |
| 2020 | $61.46B | $6.21B | 9.9× | -3.7× | |
| 2019 | $56.49B | $4.16B | 13.6× | -0.3× | |
| 2018 | $42.23B | $3.05B | 13.9× | -1.3× | |
| 2017 | $37.70B | $2.49B | 15.1× | +4.5× | |
| 2016 | $18.08B | $1.70B | 10.6× | -18.6× | |
| 2015 | $30.13B | $1.03B | 29.2× | -19.5× | |
| 2014 | $28.26B | $580.41M | 48.7× | +34.5× | |
| 2013 | $17.18B | $1.21B | 14.2× | +8.3× | |
| 2012 | $8.99B | $1.53B | 5.9× | +1.0× | |
| 2011 | $6.91B | $1.41B | 4.9× | -44.3× | |
| 2010 | $7.05B | $143.37M | 49.2× | -34.5× | |
| 2009 | $8.52B | $101.89M | 83.7× | +57.9× | |
| 2008 | $4.52B | $175.50M | 25.8× | +10.5× | |
| 2007 | $3.04B | $199.01M | 15.3× | -6.2× | |
| 2006 | $4.64B | $216.36M | 21.5× | +3.0× | |
| 2005 | $2.97B | $160.89M | 18.5× | +10.3× | |
| 2004 | $835.82M | $102.72M | 8.1× | -3.5× | |
| 2003 | $804.88M | $69.14M | 11.6× | +4.1× | |
| 2002 | $1.21B | $161.09M | 7.5× | -6.4× | |
| 2001 | $1.84B | $132.39M | 13.9× | — |
- 20259.6×
- 20249.4×
- 202310.6×
- 20228.3×
- 20217.4×
- 20209.9×
- 201913.6×
- 201813.9×
- 201715.1×
- 201610.6×
- 201529.2×
- 201448.7×
- 201314.2×
- 20125.9×
- 20114.9×
- 201049.2×
- 200983.7×
- 200825.8×
- 200715.3×
- 200621.5×
- 200518.5×
- 20048.1×
- 200311.6×
- 20027.5×
- 200113.9×
About P/S Ratio at Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals (VRTX) P/S ratio is 9.3× as of June 5, 2026. The 5-year average is 9.3×. The sector median currently stands at 3.5×. The current ratio is at the 41th percentile of its own 10-year history.
Vertex Pharmaceuticals (VRTX) historical P/S ratio has ranged from a low of 4.8× (2012) to a high of 83.7× (2009) in the available daily series.
The price-to-sales (P/S) ratio compares a company's market capitalisation to its trailing twelve-month (TTM) revenue. It is calculated as market cap ÷ TTM revenue (equivalent to share price ÷ TTM revenue per share). Because the denominator (revenue) cannot be negative, P/S is widely used to value unprofitable or pre-profit companies and to make cross-sector comparisons.
Vertex Pharmaceuticals P/S Ratio by Year
Vertex Pharmaceuticals P/S Ratio 2025: 9.6×
Vertex Pharmaceuticals (VRTX) P/S ratio in 2025 was 9.6×, expanded from 9.4× the prior year.
Vertex Pharmaceuticals P/S Ratio 2024: 9.4×
Vertex Pharmaceuticals (VRTX) P/S ratio in 2024 was 9.4×, contracted from 10.6× the prior year.
Vertex Pharmaceuticals P/S Ratio 2023: 10.6×
Vertex Pharmaceuticals (VRTX) P/S ratio in 2023 was 10.6×, expanded from 8.3× the prior year.
Vertex Pharmaceuticals P/S Ratio 2022: 8.3×
Vertex Pharmaceuticals (VRTX) P/S ratio in 2022 was 8.3×, expanded from 7.4× the prior year.
Vertex Pharmaceuticals P/S Ratio 2021: 7.4×
Vertex Pharmaceuticals (VRTX) P/S ratio in 2021 was 7.4×.
Sector peers by P/S Ratio — chart
Current ratio vs. sector peers. Highlighted bar is this company.
Sector peers by P/S Ratio — table
Healthcare peers of Vertex Pharmaceuticals (VRTX), ranked by P/S ratio.
| 2.1× | |
| 2.1× | |
| 2.1× | |
| 1.9× | |
| 1.9× | |
| 1.7× | |
| 1.6× | |
| 1.6× | |
| 1.4× | |
| 1.4× | |
| 1.1× | |
| 0.8× | |
| 0.7× | |
| 0.6× | |
| 0.6× | |
| 0.5× | |
| 0.3× | |
| 0.3× | |
| 0.3× | |
| 0.2× | |
| 0.2× | |
| 0.2× | |
| 0.2× | |
| 0.2× | |
| 0.1× |
- 2.1×
- 1.7×
- 1.4×
- 1.1×
- 0.7×
- 0.3×
- 0.3×
- 0.2×
- 0.2×
- 0.2×
- 0.1×
Frequently asked questions
Vertex Pharmaceuticals (VRTX) Key Financials
Charts, filings, and peer comparison for every metric